Related references
Note: Only part of the references are listed.225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
Mike Sathekge et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Functionally Versatile and Highly Stable Chelator for 111In and 177Lu: Proof-of-Principle Prostate-Specific Membrane Antigen Targeting
Lily Li et al.
BIOCONJUGATE CHEMISTRY (2019)
Radioactive Main Group and Rare Earth Metals for Imaging and Therapy
Thomas I. Kostelnik et al.
CHEMICAL REVIEWS (2019)
Synthesis and evaluation of bifunctional tetrahydroxamate chelators for labeling antibodies with 89Zr for imaging with positron emission tomography
Julie Rousseau et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches
Nikki A. Thiele et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2018)
Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging
Delphine Vivier et al.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS (2018)
Targeted and Nontargeted α-Particle Therapies
Michael R. McDevitt et al.
ANNUAL REVIEW OF BIOMEDICAL ENGINEERING, VOL 20 (2018)
An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth
Alfred Morgenstern et al.
CURRENT RADIOPHARMACEUTICALS (2018)
Development of Ac-225 Radiopharmaceuticals: TRIUMF Perspectives and Experiences
Andrew Kyle Henderson Robertson et al.
CURRENT RADIOPHARMACEUTICALS (2018)
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy
Ho Sze Chan et al.
PLOS ONE (2017)
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617-preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
Christoph A. Umbricht et al.
EJNMMI RESEARCH (2017)
An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy
Nikki A. Thiele et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2017)
Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors
Martina Benesova et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
225Ac-PSMA-617 for PSMA-Targeted a-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with L-lysine
Ho Sze Chan et al.
EJNMMI RESEARCH (2016)
Novel Preparation Methods of 52Mn for ImmunoPET Imaging
Stephen A. Graves et al.
BIOCONJUGATE CHEMISTRY (2015)
Preclinical Evaluation of 86Y-Labeled Inhibitors of Prostate Specific Membrane Antigen for Dosimetry Estimates
Sangeeta Ray Banerjee et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer
Martina Benesova et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Matching chelators to radiometals for radiopharmaceuticals
Eric W. Price et al.
CHEMICAL SOCIETY REVIEWS (2014)
Aqueous Complexes for Efficient Size-based Separation of Americium from Curium
Mark P. Jensen et al.
INORGANIC CHEMISTRY (2014)
Tumour targeting with radiometals for diagnosis and therapy
Caterina F. Ramogida et al.
CHEMICAL COMMUNICATIONS (2013)
Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis
Markus Essler et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
Avogadro: an advanced semantic chemical editor, visualization, and analysis platform
Marcus D. Hanwell et al.
JOURNAL OF CHEMINFORMATICS (2012)
A practical guide to the construction of radiometallated bioconjugates for positron emission tomography
Brian M. Zeglis et al.
DALTON TRANSACTIONS (2011)
Macrocyclic Receptor Showing Extremely High Sr(II)/Ca(II) and Pb(II)/Ca(II) Selectivities with Potential Application in Chelation Treatment of Metal Intoxication
Raquel Ferreiros-Martinez et al.
INORGANIC CHEMISTRY (2011)
Clinical radioimmunotherapy-the role of radiobiology
Jean-Pierre Pouget et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Actinium-225 in Targeted Alpha-Particle Therapeutic Applications
David A. Scheinberg et al.
CURRENT RADIOPHARMACEUTICALS (2011)
Radioimmunotherapy of Breast Cancer Metastases with α-Particle Emitter 225Ac: Comparing Efficacy with 213Bi and 90Y
Hong Song et al.
CANCER RESEARCH (2009)
Macrocyclic Receptor Exhibiting Unprecedented Selectivity for Light Lanthanides
Adrian Roca-Sabio et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2009)
Preclinical evaluation of the α-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors
Matthias Miederer et al.
CLINICAL CANCER RESEARCH (2008)
Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells
Claudia Friesen et al.
CANCER RESEARCH (2007)
Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities
WAP Breeman et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Design and synthesis of 225Ac radioimmunopharmaceuticals
MR McDevitt et al.
APPLIED RADIATION AND ISOTOPES (2002)
Tumor therapy with targeted atomic nanogenerators
MR McDevitt et al.
SCIENCE (2001)
Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for 225Ac radioimmunotherapy applications
LL Chappell et al.
BIOCONJUGATE CHEMISTRY (2000)
Evaluation of 225Ac for vascular targeted radioimmunotherapy of lung tumors
SJ Kennel et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2000)
Share Paper
